Oculus Commercializes Microcyn Skin and Wound Cleanser

Oculus Innovative Sciences has commercialized its Microcyn Skin and Wound Cleanser with preservatives, in both professional and over-the-counter formulations.

Reportedly, the professional product is indicated for use by health care practitioners to manage the debridement of wounds such as stage I-IV pressure ulcers, diabetic foot ulcers, post-surgical wounds, first-and-second-degree wounds, grafted and donor sites.

The company said that the OTC product is indicated for use in cleansing of dirt and debris from lacerations, skin abrasions, minor burns and minor irritations of the skin.

The company, in partnership with Advocos, is marketing the Microcyn Skin and Wound Cleanser with preservative to medical professionals.

The company claims that the Microcyn Skin and Wound Cleanser with preservatives, which received FDA 510(k) clearance in May of this year, has demonstrated rapid activity against a broad spectrum of gram-positive, gram-negative and yeast species.

Hoji Alimi, founder and CEO of Oculus, said: “These impressive in vitro kill times further validate the Microcyn Technology’s unique and proprietary mode of action. At the same time, the Microcyn solution is safe as saline. This safety profile simply can’t be equaled by silver-based products or even Dakin’s solution, better known as diluted bleach, which actually impede wound healing.